January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
5 citations
,
April 2023 in “Life” CCCA affects adolescents too, with genetic and environmental links, requiring careful diagnosis.
May 2018 in “Dermatologic Surgery” 4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
6 citations
,
February 2025 in “Scientific Reports” MEGA PROTAC improves prediction and ranking of protein complexes better than existing methods.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
1 citations
,
September 2024 in “Indian Journal of Postgraduate Dermatology” Trichoscopy effectively diagnoses temporal triangular alopecia in children.
5 citations
,
July 1996 in “Journal of Cutaneous Medicine and Surgery” TTD patients don't have a higher skin cancer risk because their main issue is with transcription, not DNA repair.
75 citations
,
March 2009 in “Journal of The American Academy of Dermatology” CCCA is a hair loss type affecting African women, possibly caused by grooming and chemicals, with various treatments and needing more research.
35 citations
,
September 2011 in “The Journal of Dermatology” Trichoscopy helps accurately diagnose temporal triangular alopecia.
28 citations
,
July 2007 in “Development” TAF4 is important for skin cell growth and helps prevent skin cancer in mice.
Introducing the OTC gene improved symptoms in mice with OTC deficiency.
156 citations
,
October 1996 in “Science of The Total Environment” Tributyltin exposure causes sex changes, sterilization, and decline in the snail Ocinebrina aciculata, risking its extinction.
February 2026 in “Chemical Engineering Journal” PCA hydrogel promotes hair growth by enhancing blood vessel formation and hair follicle stem cell activity.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
July 2024 in “JAAD Case Reports” Corticosteroid injections for hair loss may cause eye problems, so caution is needed.
45 citations
,
March 1997 in “Journal of Investigative Dermatology” September 2025 in “Stem Cell Research & Therapy” TAZ boosts fat cell formation in goat stem cells by activating a specific signaling pathway.
July 2023 in “JAAD Case Reports”
Radiofrequency microneedling improves the absorption of topical triamcinolone acetonide, especially with deeper needle insertion.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
3 citations
,
April 2022 in “Cutis” CCCA is a common, scarring hair loss in Black women that needs early detection.
11 citations
,
January 2013 in “Indian Dermatology Online Journal” CCCA is a common, progressive hair loss condition that may not always be linked to hair care practices and requires a biopsy for diagnosis.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.